CDKN2A and meningioma: The hypothesis of this study is that MTAP and p16 expression as assessed by IHC can act as reliable surrogate markers for detecting homozygous CDKN2A/B loss in meningiomas, providing a cost-effective alternative to more expensive and less accessible molecular techniques.